Asia-Pacific
IP lawyers at three firms reflect on how courts across Australia have reacted to AI use in litigation, and explain why they support measured use of the technology
Tilleke & Gibbins topped the leaderboard with four awards across the region, while Anand & Anand and Kim & Chang emerged as outstanding domestic firms
Andrew Blattman, who helped IPH gain significant ground in Asia and Canada, will leave in the second half of 2026
Vivien Chan joins us for our ‘Women in IP’ series to discuss gender bias in the legal profession and why the business model followed by law firms leaves little room for women leaders
Sponsored
Sponsored
-
Sponsored by Saint Island International Patent & Law OfficesMing-Yeh Lin of Saint Island International Patent & Law Offices reports on a Taiwanese Intellectual Property and Commercial Court ruling that has ramifications for whether certain private documents can serve as prior art references -
Sponsored by Bird & BirdMeyke Rietveld and Clemens Molle of Bird & Bird, along with Emma Ren from the association team at Beijing Lawjay Partners, discuss the first copyright cases in China and the EU dealing with training AI models, and newly enacted legislation in this field
-
Sponsored by Tilleke & GibbinsLoc Xuan Le, Duc Anh Tran, and Linh Duy Mai of T&G Law Firm LLC, the local associate firm of Tilleke & Gibbins in Vietnam, report on the country’s first criminal trial involving copyright and related rights infringement
-
Sponsored by Tilleke & GibbinsLinh Thi Mai Nguyen and Chi Lan Dang of Tilleke & Gibbins say regulations concerning the new Inspection and Appeal Department and a 2023 circular are steps towards improved handling of intellectual property appeals
-
Sponsored by Remfry & SagarAarti Aggarwal of Remfry & Sagar reports that a decision concerning a company licensed to use the Nokia brand name has confirmed that generic concepts or ideas cannot be protected through copyright
-
Sponsored by RNA, Technology and IP AttorneysRanjan Narula and Suvarna Pandey of RNA, Technology and IP Attorneys consider the implications of a High Court of Delhi ruling concerning a patented compound used to treat non-small cell lung cancer
